Nitric oxide-releasing vehicles for biomedical applications

Abstract

Nitric oxide (NO) is involved in several physiological processes, such as the control of vascular tone, the inhibition of platelet aggregation, smooth muscle cell replication, the immune response, and wound healing processes. Several pathologies have been associated with dysfunctions in the endogenous production of NO. Thus, there is great interest in developing NO-releasing drugs and in matrices which are able to stabilize and release NO locally and directly in different tissues. Over the past few years, a very promising strategy for biocompatible NO-delivery systems has emerged based on the use of nanobiotechnology for targeted NO-release for biomedical applications. In this work, the current stateof-the-art approaches to NO-release from nanomeric materials, their preparation, and promising biomedical applications are reviewed. Such materials, comprised of dendrimers, liposomes, metallic and silica nanoparticles, polymeric micro and nanoparticles, semiconductor quantum dots, carbon nanotubes, and nanoporous solid materials exhibit exceptional potential in directly delivering NO in a controlled spatial and temporal manner with superior biocompatibility for pharmacological applications.

Comparative assessment of the apoptotic potential of silver nanoparticles synthesized by Bacillus tequilensis and Calocybe indica in MDA-MB-231 human breast cancer cells: targeting p53 for anticancer therapy

“…Capping agents are essential for preventing nanoparticle aggregation and increasing solubility of the nanosystem, and they can also be used as a site for bioconjugation of the nanoparticle with important molecules. 12,13 Stabilization of nanoparticles can be achieved by adding capping agents, which bind to the nanoparticle surface via covalent bonds or chemical interactions. 14 Thus, biologically prepared nanomaterials are extremely valuable because nanoparticles can be coated with a lipid or protein layer that confers physiological solubility and stability, which are critical parameters for biomedical applications that are currently a challenge for other synthesis methods.…”

Nanotoxicology of Metal Oxide Nanoparticles

“…TiO2 nanoparticles have important environmental, technological and biomedical applications [51,55]. Jha and Prasad [56] reported the reproducible room temperature biosynthesis of TiO2 nanoparticles (10-70 in size) by Lactobacillus sp.…”

“…Silica nanoparticles are important nanomaterials in biomedical applications such as nanocarriers for drug delivery systems [50,51]. Silica nanoparticles are widely used in industry, biomedical engineering and cosmetics [52].…”

Nitric oxide releasing-dendrimers: an overview

“…Together with other types of matrices (Tfouni et al, 2010;Seabra, Durán, 2010;Saraiva et al, 2011;Riccio, Schoenfisch, 2012), dendrimers have been used as NOreleasing carriers platforms (Taite, West, 2006;Stasko, Schoenfisch, 2006;Stasko, Fischer, Schoenfisch, 2008;Benini, McGarvey, Franco, 2008;Lu et al, 2011). One of the advantages of the NO-donors dendrimers over others NO carriers systems is their ability of storage high concentrations of nitric oxide per unit of drug carrier.…”

“…A reasonable volume of the current research have been focused on attaching NO releasing compounds to different platforms (Eroy-Reveles, Mascharak, 2010;Tfouni et al, 2010;Seabra, Durán, 2010;Riccio, Schoenfisch, 2012;Jen et al, 2012), as nanoparticles (Friedman et al, 2008;Seabra, Durán, 2010), silica gel (Zanichelli, Sernaglia, Franco, 2006;Doro, Rodrigues-Filho, Tfouni, 2007), xerogels and dendrimers (Stasko, Schoenfisch, 2006;Stasko, Fischer, Schoenfisch, 2008;Benini, McGarvey, Franco, 2008;Lu et al, 2011). These strategies aimed to improve NO-donors stability (Lu et al, 2011), promote a high payload of nitric oxide on a single platform (Stasko, Schoenfisch, 2006;Stasko, Fischer, Schoenfisch, 2008) and achieve specific targets (Taite, West, 2006).…”